Stock Events

Stock Events

Cartesian Therapeutics 

€7.05
73
+€0.35+5.22% Wednesday 06:05

Statistics

Day High
7.05
Day Low
7.05
52W High
11.6
52W Low
5.4
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q4 2025
Q1 2026
Next
-2.98
-2.23
-1.48
-0.73
Expected EPS
-0.7551177915
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1S70.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Allogene Therapeutics
ALLO
Mkt Cap786.66M
Allogene Therapeutics is involved in the development of allogeneic CAR-T therapies, competing in the same space as Cartesian's cell therapy products.
CRISPR Therapeutics
CRSP
Mkt Cap5.29B
CRISPR Therapeutics is engaged in gene editing and cell therapy, including CAR-T therapies, which puts them in direct competition with Cartesian.
Novartis
NVS
Mkt Cap278.64B
Novartis is a large pharmaceutical company with Kymriah, a CAR-T cell therapy for cancer, making it a competitor in Cartesian's market.
Gilead Sciences
GILD
Mkt Cap163.06B
Gilead Sciences, owning Kite Pharma, competes in the CAR-T and cell therapy space, directly challenging Cartesian's therapeutic approaches.
Pfizer
PFE
Mkt Cap146.36B
Pfizer is involved in various therapeutic areas, including investments in gene therapy and cell therapy, potentially competing with Cartesian's technologies.

About

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Show more...
CEO
Dr. Carsten Brunn Ph.D.
Employees
37
Country
United States
ISIN
US8162123025

Listings

MU
DE
1S70.MU
STU
DE
1S70.STU
BOATS
BOATS
RNAC.BOATS
F
DE
1S70.F

0 Comments

Share your thoughts

FAQ

What is Cartesian Therapeutics stock price today?▼
The current price of 1S70.MU is €7.05 EUR — it has increased by +5.22% in the past 24 hours. Watch Cartesian Therapeutics stock price performance more closely on the chart.
What is Cartesian Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cartesian Therapeutics stocks are traded under the ticker 1S70.MU.
Is Cartesian Therapeutics stock price growing?▼
1S70.MU stock has risen by +5.22% compared to the previous week, the month change is a +30.56% rise, over the last year Cartesian Therapeutics has showed a -24.19% decrease.
When is the next Cartesian Therapeutics earnings date?▼
Cartesian Therapeutics is going to release the next earnings report on August 06, 2026.
What were Cartesian Therapeutics earnings last quarter?▼
1S70.MU earnings for the last quarter are -1.24 EUR per share, whereas the estimation was -0.74 EUR resulting in a -67.86% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Cartesian Therapeutics have?▼
As of May 17, 2026, the company has 37 employees.
In which sector is Cartesian Therapeutics located?▼
Cartesian Therapeutics operates in the Health & Wellness sector.
When did Cartesian Therapeutics complete a stock split?▼
The last stock split for Cartesian Therapeutics was on December 01, 2023 with a ratio of 1:1.
Where is Cartesian Therapeutics headquartered?▼
Cartesian Therapeutics is headquartered in Gaithersburg, United States.